New combination therapy is game-changer in treatment of type 2 diabetes


Dr. Ravi Retnakaran, an endocrinologist at the Sinai Diabetes Leadership Center at Mount Sinai Hospital, as well as a scientist at the hospital's Lunenfeld-Tanenbaum Research Institute, discusses the importance of his team's recent study at The Lancet for patients with type 2 diabetes. Your team shows that, when combined with long-acting insulin, a new class of medication that mimics a natural gut hormone can get excellent control of blood sugar, without an increased risk of low levels of sugars or weight gain, which are common side effects of current drug treatments for patients with type 2 diabetes. Based on the results of the study, the Mount Sinai Hospital research team is starting a new clinical trial (called PREVAIL) of this combination therapy. Patients are encouraged to call the Sinai Diabetes Leadership Center at Mount Sinai Hospital for more information, or click here:

Video credits to Lunenfeld-Tanenbaum YouTube channel





  • Your reaction?
    Angry Angry
    0
    Angry
    Lol Lol
    0
    Lol
    Love It! Love It!
    0
    Love It!
    Nice Nice
    0
    Nice
    Now I Know Now I Know
    0
    Now I Know
    Sad Sad
    0
    Sad
    Surprised Surprised
    0
    Surprised
    Wow! Wow!
    0
    Wow!
    WTF WTF
    0
    WTF

    New combination therapy is game-changer in treatment of type 2 diabetes

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    log in

    reset password

    Back to
    log in